[go: up one dir, main page]

MX2018008448A - Reducción de especies de alto peso molecular, especies con carga ácida, y fragmentos en una composición de anticuerpo monoclonal. - Google Patents

Reducción de especies de alto peso molecular, especies con carga ácida, y fragmentos en una composición de anticuerpo monoclonal.

Info

Publication number
MX2018008448A
MX2018008448A MX2018008448A MX2018008448A MX2018008448A MX 2018008448 A MX2018008448 A MX 2018008448A MX 2018008448 A MX2018008448 A MX 2018008448A MX 2018008448 A MX2018008448 A MX 2018008448A MX 2018008448 A MX2018008448 A MX 2018008448A
Authority
MX
Mexico
Prior art keywords
species
molecular weight
high molecular
level
monoclonal antibodies
Prior art date
Application number
MX2018008448A
Other languages
English (en)
Inventor
Santoro Marc
John Jose Kevin
Madabhushi Sri
Gangloff Scott
Original Assignee
Oncobiologics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncobiologics Inc filed Critical Oncobiologics Inc
Publication of MX2018008448A publication Critical patent/MX2018008448A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
    • C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M21/00—Bioreactors or fermenters specially adapted for specific uses

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Las alteraciones en la alimentación de cultivo celular en biorreactor a una alimentación prolongada o continua después de un periodo inicial de no alimentación reducen el nivel de alto peso molecular, carga ácida, y las especies de fragmentos de anticuerpos monoclonales expresados en el cultivo, y mejora el nivel de las especies afucosiladas de los anticuerpos monoclonales expresados en el cultivo. Las infusiones de fucosa regulares después de un periodo inicial de no infusión de medio de alimentación reducen el nivel de especies afucosiladas de anticuerpos monoclonales expresados en el cultivo. La manipulación del cultivo celular puede utilizarse para modular el nivel de las especies de anticuerpos monoclonales.
MX2018008448A 2016-01-06 2017-01-05 Reducción de especies de alto peso molecular, especies con carga ácida, y fragmentos en una composición de anticuerpo monoclonal. MX2018008448A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662275386P 2016-01-06 2016-01-06
PCT/US2017/012362 WO2017120359A1 (en) 2016-01-06 2017-01-05 Reduction of high molecular weight species, acidic charge species, and fragments in a monoclonal antibody composition

Publications (1)

Publication Number Publication Date
MX2018008448A true MX2018008448A (es) 2019-05-30

Family

ID=57944514

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018008448A MX2018008448A (es) 2016-01-06 2017-01-05 Reducción de especies de alto peso molecular, especies con carga ácida, y fragmentos en una composición de anticuerpo monoclonal.

Country Status (8)

Country Link
US (1) US20190048070A1 (es)
EP (1) EP3400242A1 (es)
JP (1) JP2019500878A (es)
CN (1) CN109153717A (es)
AU (1) AU2017206012A1 (es)
CA (1) CA3010600A1 (es)
MX (1) MX2018008448A (es)
WO (1) WO2017120359A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014337263B2 (en) 2013-10-16 2019-12-12 Outlook Therapeutics, Inc. Buffer formulations for enhanced antibody stability
US10696735B2 (en) 2015-01-21 2020-06-30 Outlook Therapeutics, Inc. Modulation of charge variants in a monoclonal antibody composition
CN109563161A (zh) 2016-02-03 2019-04-02 安口生物公司 用于提高抗体稳定性的缓冲制剂
CA3093853A1 (en) 2018-03-26 2019-10-03 Amgen Inc. Total afucosylated glycoforms of antibodies produced in cell culture
HU231514B1 (hu) * 2018-11-07 2024-07-28 Richter Gedeon Nyrt. Sejttenyészetben előállított rekombináns glikoprotein glikozilációs mintázatának megváltoztatására szolgáló módszer
EP4284834A1 (en) * 2021-01-29 2023-12-06 Merck Sharp & Dohme LLC Compositions of programmed death receptor 1 (pd-1) antibodies and methods of obtaining the compositions thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992013876A1 (en) * 1991-02-01 1992-08-20 Coulter Corporation METHOD OF PRODUCING F(ab')2 FRAGMENTS OF IMMUNOGLOBULINS
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
AR058140A1 (es) * 2005-10-24 2008-01-23 Wyeth Corp Metodo de produccion proteica utilizando compuestos anti-senescencia
JP5576115B2 (ja) * 2007-04-26 2014-08-20 中外製薬株式会社 高濃度アミノ酸含有培地を用いた細胞の培養方法
AU2010256455A1 (en) * 2009-06-05 2012-01-19 Momenta Pharmaceuticals, Inc. Methods of modulating fucosylation of glycoproteins
JP6001456B2 (ja) * 2010-12-28 2016-10-05 中外製薬株式会社 動物細胞の培養方法
WO2013006479A2 (en) * 2011-07-01 2013-01-10 Amgen Inc. Mammalian cell culture
WO2013114165A1 (en) * 2012-01-30 2013-08-08 Dr Reddy's Laboratories Limited Process of obtaining glycoprotein composition with increased afucosylation content
WO2013114164A1 (en) * 2012-01-30 2013-08-08 Dr. Reddy's Laboratories Limited Method for obtaining glycoprotein composition with increased afucosylation content
NO2760138T3 (es) * 2012-10-01 2018-08-04
EP2906683B1 (en) * 2012-10-15 2017-05-31 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
WO2014175164A1 (ja) * 2013-04-25 2014-10-30 株式会社カネカ Ｆａｂ型抗体の分泌量を増大できるＦｄ鎖遺伝子又はＬ鎖遺伝子
WO2015140700A1 (en) * 2014-03-19 2015-09-24 Dr. Reddy's Laboratories Limited Cell culture process
CN105779394B (zh) * 2015-03-20 2020-03-24 广东东阳光药业有限公司 一种降低抗体酸性峰含量和改良抗体糖型的细胞培养方法

Also Published As

Publication number Publication date
AU2017206012A1 (en) 2018-07-26
CN109153717A (zh) 2019-01-04
JP2019500878A (ja) 2019-01-17
US20190048070A1 (en) 2019-02-14
WO2017120359A1 (en) 2017-07-13
CA3010600A1 (en) 2017-07-13
EP3400242A1 (en) 2018-11-14

Similar Documents

Publication Publication Date Title
MX2018008447A (es) Modulacion de especies afucosilados en una composicion de anticuerpo monoclonal.
MX2018008448A (es) Reducción de especies de alto peso molecular, especies con carga ácida, y fragmentos en una composición de anticuerpo monoclonal.
PH12017500918A1 (en) Antibodies against cd73 and uses thereof
GEP20237513B (en) Improved methods for enhancing antibody productivity in mammalian cell culture and minimizing aggregation during downstream, formulation processes and stable antibody formulations obtained thereof
ZA201703241B (en) Anti-c5 antibodies and methods of use
SG10201903912XA (en) Delivery of biomolecules to immune cells
MX2018006973A (es) Anticuerpos anti-cd73 humanizados.
EP4303229A3 (en) Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules
EP4530630A3 (en) Monoclonal antibodies and methods of use
PH12018501282A1 (en) Anti-c5 antibodies and methods of use
HK1255161A1 (zh) 用於过继性细胞治疗的工程细胞
NZ631197A (en) Anti sez6 antibodies and methods of use
HK1243631A1 (zh) 用於提高过继细胞免疫疗法效力的组合物和方法
NZ602220A (en) Antibodies with ph dependent antigen binding
EP4282881A3 (en) Antibodies against csf-1r
IL276910A (en) Fully fucose-free glycoforms of antibodies are produced in cell culture
AU2016335217A8 (en) Antigen receptors and uses thereof
IL269197A (en) Control of fully apocosylated antibody glycoforms produced in cell culture
MX2015011781A (es) Medio de cultivo celular y metodos de produccion de anticuerpos.
MX2015010428A (es) Anticuerpos anti-her2 altamente galactosilados y sus usos.
IN2014MU01100A (es)
MY193535A (en) Cell culture methods
MX2012002829A (es) Producción de una respuesta inmune para disminuir el riesgo de contagio por brucelosis.
MX2016013363A (es) Metodo para aumentar la capacidad de sintesis de biomasa de microorganismos y microorganismos modificados a partir de ellos.
MX2016006390A (es) Metodo de alimentacion animal con masas de celulas de fermentacion.